NCT06240728 - A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Metastatic Malignant Neoplasm

Interventions

DRUG

NPX887

NPX887 will be administered by IV infusion every 3 weeks until documented disease progression or participant withdrawal for up to 2 years

Trial Locations (8)

ACTIVE_NOT_RECRUITING

Albert Einstein Medical College Montefiore Medical Center, The Bronx

ACTIVE_NOT_RECRUITING

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore

ACTIVE_NOT_RECRUITING

NEXT Oncology-Fairfax, Fairfax

ACTIVE_NOT_RECRUITING

MD Anderson Cancer Center, Houston

ACTIVE_NOT_RECRUITING

Next Oncology, San Antonio

ACTIVE_NOT_RECRUITING

Beth Israel Deaconess Medical Center (BIDMC), Boston

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

RECRUITING

Samsung Medical Center, Seoul